OCC 1.16% 42.5¢ orthocell limited

Ann: Quarterly Activity Report & Appendix 4C, page-17

  1. 772 Posts.
    lightbulb Created with Sketch. 219
    Steady as she goes. Unfortunately current sentiment just not there for emerging biotech. Money in the bank, no debt, decent pipeline and revenues increasing. A lot to like but it’s a slow train. GLTA
 
watchlist Created with Sketch. Add OCC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.